सभी अध्ययन
अधिकृतचरण I और चरण II (एकीकृत) - अन्यहस्तक्षेपात्मक

Phase 1/2 Open-Label Trial to Evaluate the Safety, Tolerability, Biological Activity, and Clinical Efficacy of intracisterna Magna administration of an AAV9 Vector Encoding Human ASAH1 (GNT0009) in Patients with Spinal Muscular Atrophy with Progressive Myoclonic Epilepsy (SMA-PME)

Spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME) is a very rare genetic condition that causes muscle weakness and severe seizures. This Phase 1/2 clinical trial is testing an experimental gene therapy called GNT0009. GNT0009 works by delivering a healthy copy of the missing or faulty gene (ASAH1) directly into the fluid around the base of the brain. The goal is to provide the body with the instructions it needs to protect nerve cells. Participants also receive medicines that calm the immune system, such as steroids, to stop the body from rejecting the treatment. Doctors will closely track safety, side effects, movement, breathing, and quality of life over 48 weeks, with long-term safety checks continuing for up to five years. People of any age with confirmed SMA-PME may be able to take part.

एक नजर में

स्थिति
अधिकृत
चरण
चरण I और चरण II (एकीकृत) - अन्य
प्रायोजक
Genethon
नामांकन लक्ष्य
3
प्रारंभ
09 Nov 2026

यह अध्ययन किस बारे में है?

Spinal muscular atrophy with progressive myoclonic epilepsy, or SMA-PME, is an extremely rare inherited condition. It happens when a specific gene, called ASAH1, does not work properly. Over time, this leads to progressive muscle weakness, wasting, and recurring seizures that are often hard to control with standard medicines. Currently, there is no cure, and available treatments only help manage the day-to-day symptoms.

This clinical trial is testing an experimental gene therapy named GNT0009. Gene therapy aims to tackle the root cause of the disease rather than just treating symptoms. GNT0009 uses a harmless, modified virus shell to carry a working copy of the human ASAH1 gene straight to nerve cells. It is given as a single injection into the fluid space at the base of the skull, allowing the treatment to reach the brain and spinal cord directly.

Because the body's natural defences might see the gene therapy as an invader, participants also take temporary immune-calming medicines, including steroids and other specialist drugs. These medicines help ensure the gene therapy has the best chance to work safely.

This trial matters because it is one of the first studies exploring a targeted genetic treatment for SMA-PME. Researchers hope to learn whether GNT0009 is safe, well-tolerated, and capable of slowing down or stabilising muscle weakness, seizures, and breathing difficulties.

मुख्य निष्कर्ष

  • Tests an experimental gene therapy (GNT0009) for people with SMA-PME.
  • Aims to replace the faulty ASAH1 gene to protect nerve and muscle cells.
  • Given as a single injection into the fluid at the base of the skull.
  • Includes temporary medicines to keep the immune system calm.
  • Participants will be closely supported and monitored for up to five years.

कौन पात्र हो सकता है?

This study is open to both males and females of any age who have a confirmed diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME). Because this condition is so rare, doctors assess each potential participant on an individual basis.

To join, participants must be able to undergo the injection procedure safely and be well enough to take medicines that temporarily lower the immune system. Certain medical conditions, severe active infections, or allergies to the study drugs may mean someone cannot take part.

Your specialist doctor or the study team will review your full medical history, genetic test results, and current health to confirm whether this trial is a safe and suitable option for you or your child.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. You or your child has a confirmed diagnosis of SMA-PME.
  2. A genetic test has shown an issue with the ASAH1 gene.
  3. You are well enough to receive an injection into the fluid space around the brain.
  4. You can safely take temporary immune-suppressing medicines like steroids.
  5. You are able to attend regular hospital check-ups over the next few years.
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

Taking part begins with detailed health screening, including blood tests, heart checks, and nerve scans, to make sure the trial is safe for you. If you join, you will be given medicines to help calm your immune system before receiving the gene therapy.

The gene therapy (GNT0009) is given as a one-off injection into the fluid at the base of the skull (an area called the cisterna magna) by an experienced specialist team in hospital. You will stay in hospital for close observation following the procedure.

After the injection, you will attend regular clinic visits over the first 48 weeks. During these visits, doctors will check your vital signs, muscle strength, breathing, hearing, thinking skills, and general wellbeing. Following the main 48-week period, the study team will continue checking on your health and safety periodically for up to five years in total.

संभावित जोखिम और लाभ

This trial may or may not improve your symptoms. However, it could help researchers understand if gene therapy can slow or stop the progression of SMA-PME in the future. The treatment carries risks, including side effects from the injection near the brain, allergic reactions, and potential side effects from immune-suppressing medicines (such as a higher chance of picking up common infections). You will be monitored very closely throughout the trial. Taking part is completely voluntary, and you have the right to withdraw at any time without it affecting your usual NHS medical care.

स्थान (1)

कुछ साइट स्थान अनुमानित हैं। हम इसे सुधार रहे हैं — कृपया यात्रा करने से पहले परीक्षण टीम से सत्यापित करें।.
  • —
    असत्यापित
    फ्रांस

सामान्य प्रश्न

What is gene therapy?

Gene therapy is a technique that introduces a healthy, working copy of a gene into the body's cells to help treat or prevent a genetic disease.

उपचार कैसे दिया जाता है?

GNT0009 is given as a single injection into the fluid at the base of the skull so that it can travel directly to the brain and spinal cord.

Why are immune-suppressing medicines needed?

Your immune system naturally fights off unfamiliar substances. Medicines like steroids are used temporarily to prevent your body from attacking the harmless carrier virus used to deliver the gene.

अध्ययन कितने समय तक चलता है?

The main intensive study period lasts 48 weeks, but the research team will keep in touch to check your health for up to five years.

Can I leave the trial if I change my mind?

Yes. Taking part is entirely your choice. You can step down from the study at any point, and your standard medical care will continue as normal.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.